- Home
- LODE vs CHRS Comparison
LODE vs CHRS Comparison
Compare LODE & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LODE
- CHRS
- Stock Information
- Founded
- LODE 2008
- CHRS 2010
- Country
- LODE United States
- CHRS United States
- Employees
- LODE N/A
- CHRS N/A
- Industry
- LODE Major Chemicals
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LODE Industrials
- CHRS Health Care
- Exchange
- LODE Nasdaq
- CHRS Nasdaq
- Market Cap
- LODE 92.1M
- CHRS 100.9M
- IPO Year
- LODE N/A
- CHRS 2014
- Fundamental
- Price
- LODE $0.31
- CHRS $0.74
- Analyst Decision
- LODE Buy
- CHRS Strong Buy
- Analyst Count
- LODE 1
- CHRS 4
- Target Price
- LODE $2.60
- CHRS $6.13
- AVG Volume (30 Days)
- LODE 2.2M
- CHRS 2.7M
- Earning Date
- LODE 10-22-2024
- CHRS 11-06-2024
- Dividend Yield
- LODE N/A
- CHRS N/A
- EPS Growth
- LODE N/A
- CHRS N/A
- EPS
- LODE N/A
- CHRS N/A
- Revenue
- LODE $1,864,811.00
- CHRS $304,340,000.00
- Revenue This Year
- LODE $80.00
- CHRS $3.33
- Revenue Next Year
- LODE $47.60
- CHRS $16.77
- P/E Ratio
- LODE N/A
- CHRS N/A
- Revenue Growth
- LODE 117.46
- CHRS 44.19
- 52 Week Low
- LODE $0.13
- CHRS $0.66
- 52 Week High
- LODE $0.72
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- LODE 34.34
- CHRS 39.72
- Support Level
- LODE $0.32
- CHRS $0.77
- Resistance Level
- LODE $0.46
- CHRS $0.89
- Average True Range (ATR)
- LODE 0.04
- CHRS 0.08
- MACD
- LODE -0.01
- CHRS 0.01
- Stochastic Oscillator
- LODE 17.23
- CHRS 28.47
About LODE Comstock Inc.
Comstock Inc is engaged in technologies that efficiently use wasted and under-utilized natural resources to produce renewable energy and other products that contribute to balancing uses and emissions of carbon and enhance mineral and material discoveries. The segments of the company are Fuels Metals, Mining, Strategic Investments, and Corporate. The company derives maximum revenue from Strategic Investments segment. The Strategic Investments Segment includes minority equity investments in Quantum Generative Materials LLC (physics-based artificial intelligence), Green Li-ion Pte Limited (lithium-ion battery recycling and cathode production), Sierra Springs Opportunity Fund (strategic direct investment in northern Nevada real estate), and other equity or equity-linked investments.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.